Search for Topics:
Title/Keyword
Journal
Submission Status
Category
 
 
Topics
Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development, 2nd...
Submit your Manuscript Submit your Abstract Propose a Topic

Topic Menu

► Topic Menu

Topic Editors

Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain
Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, Universidad de Navarra, Pamplona, Spain
Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, CP 28040 Madrid, Spain
share announcement

Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development, 2nd Edition

Abstract submission deadline
30 January 2027
Manuscript submission deadline
30 April 2027
Viewed by
706

Topic Information

Dear Colleagues,

Pharmacometrics represents a valuable methodology to increase the efficiency of the drug discovery, development and use of medicines. The three basic pillars of Pharmacometrics are the thorough and detailed understanding of the disease and the drug, the development of mathematical models able to integrate information from different sources (in vitro, in vivo and in silico) and the ability to apply these strategies during the drug development process, regulatory review and clinical use.

This Topic aims to highlight the role of pharmacometrics at the preclinical and clinical level, focusing on new modeling strategies and methodologies, characterizing the PK or PK/PD properties of drugs together with placebo and disease models, and optimizing dosing schedules in special sub-groups of populations in order to identify new therapeutic agents/targets and/or understanding of complex biological systems.

Dr. Victor Mangas Sanjuán
Prof. Dr. Inaki F. Troconiz
Dr. Maria Garcia-Cremades Mira
Topic Editors

Keywords

  • pharmacometrics
  • pharmacokinetics
  • pharmacodynamics
  • physiologically based pharmacokinetic
  • modelling
  • population approach
  • therapeutic drug monitoring

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Pharmaceutics
pharmaceutics 		5.5 10.0 2009 15.7 Days CHF 2900 Submit
Pharmaceuticals
pharmaceuticals 		4.8 7.7 2004 16 Days CHF 2900 Submit
Antibiotics
antibiotics 		4.6 8.7 2012 16.4 Days CHF 2900 Submit
Scientia Pharmaceutica
scipharm 		2.5 4.6 1930 22.8 Days CHF 1000 Submit
Journal of Pharmaceutical and BioTech Industry
jpbi 		- - 2024 15.0 days * CHF 1000 Submit

* Median value for all MDPI journals in the second half of 2025.


Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
14 pages, 1361 KB  
Article
Influence of CYP2D6, CYP2C19, and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients
by Levin Thomas, Carla González de la Cruz, Carmen Mata-Martín, Idian González-Rodríguez, Idilio González-Martínez, Eva M. Peñas-Lledó and Adrián LLerena
Pharmaceuticals 2026, 19(2), 209; https://doi.org/10.3390/ph19020209 - 26 Jan 2026
Viewed by 371
Abstract
Background/Objectives: Venlafaxine has been reported to exhibit significant interindividual pharmacokinetic heterogeneity across populations, which has been linked to cytochrome P450 polymorphisms and clinical factors. This study aimed to assess the impact of pharmacogenetic (PGx) and clinical determinants on the dose-normalized venlafaxine/O-desmethylvenlafaxine (ODV) [...] Read more.
Background/Objectives: Venlafaxine has been reported to exhibit significant interindividual pharmacokinetic heterogeneity across populations, which has been linked to cytochrome P450 polymorphisms and clinical factors. This study aimed to assess the impact of pharmacogenetic (PGx) and clinical determinants on the dose-normalized venlafaxine/O-desmethylvenlafaxine (ODV) metabolic ratios (MRs) in routine clinical settings in Spain. Methods: 29 adult patients receiving venlafaxine were prospectively recruited through the MedeA PGx Implementation Strategy into clinical practice (Extremadura, Spain). CYP2D6, CYP2C19, and CYP2C9 genotypes were determined using TaqMan® assays, and CYP2D6 activity scores were assigned based on allele functionality. Steady-state trough plasma concentration of venlafaxine and ODV were measured using a validated high-performance liquid chromatography method. Dose-normalized venlafaxine/ODV MRs were compared across CYP2D6-, CYP2C19-, and CYP2C9-genotype-predicted metabolizer groups. The influence of demographic and clinical variables on dose-normalized venlafaxine/ODV MR was also assessed. Results: Significant variability in dose-normalized venlafaxine/ODV MRs was observed across CYP2D6 (p = 0.019) and CYP2C19 (p = 0.008) metabolizer groups. Among clinical variables, sex was significantly associated with differences in dose-normalized venlafaxine/ODV MR (p = 0.0006). Conclusions: CYP2D6 and CYP2C19 genotypes and sex significantly contribute to variability in venlafaxine metabolism in patients treated in routine clinical settings. These results highlight the value of combining PGx and clinical data with drug plasma concentration measurement to optimize venlafaxine therapy within PGx implementation programs. Full article
(This article belongs to the Topic Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development, 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop